Loading…
← CockpitCompetitor Analysis › 603108.SS Shanghai Runda Medical Technology Co., Ltd. Class AOpen in the cockpit ↗

Shanghai Runda Medical Technology Co., Ltd. Class A603108.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum weak 29
Mkt cap
$744M
US dollars, full cap
Free float
66%
of shares outstanding
$/day
$35.5M
20-day average traded
Fwd P/E
20.5×
forward earnings
ROIC−WACC
-4.0 pp
WACC 5.0%
Hurdle
+20 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥8.51
1D-5.8%
1W-18.0%
1M-14.0%
3M-19.3%
6M-35.7%
YTD-43.1%
1Y-49.4%
ATR %6.3%
52w lowhigh59.0% off high

What Shanghai Runda Medical Technology does

Employees: 2,945

Shanghai Runda Medical Technology at a glance

Size Shanghai Runda Medical Technology (603108.SS) is a China Health Care company (Medical Specialties) with a market value of $744M, the 2754th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.51 on 18 Nov 2026.

Performance Over six months the shares fell 35.7%, against -13.5% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue fell 11.9% over the last twelve months (peer median +13.0%); the operating margin is -2.3% (peer median 14.1%).

Valuation It trades at 20.5× forward earnings against a peer median of 19.8× (7th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.0 points below its cost of capital (5.0% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 88603108.SS 62
Six months, rebased to 100: Shanghai Runda Medical Technology against the median of its 20 peers (local-currency closes).

Shanghai Runda Medical Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.52BCN¥6.98BCN¥8.28BCN¥9.11BCN¥10.5B
Revenue growth—-16%-9%-13%—
Gross profitCN¥1.71BCN¥1.39BCN¥1.98BCN¥2.30BCN¥2.82B
EBITDAn/aCN¥371MCN¥968MCN¥1.11BCN¥1.40B
Net income-CN¥559M-CN¥548MCN¥55.3MCN¥273MCN¥418M
Free cash flowCN¥724MCN¥442MCN¥444MCN¥482M-CN¥663M
Capital expenditureCN¥237MCN¥250MCN¥229MCN¥320MCN¥272M
Total debtCN¥5.81BCN¥6.96BCN¥7.09BCN¥6.91BCN¥7.04B

Quarterly statements and history in the cockpit →

Shanghai Runda Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%300453INMD0029506008553013676881796881083004633011222190VREX1302CTKBMLABBBNX300622SETL6884107575603108.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Runda Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×300453INMD301367688179688108300463301122VREX688410603108.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Runda Medical Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%300453INMD688179688108300463219013027575603108.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Runda Medical Technology is the large dot.

Shanghai Runda Medical Technology competitors and peer comparison

How Shanghai Runda Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Runda Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure603108.SSPeer medianRank in peer set
1-month return-14.0%-6.7%5th lowest of 21
6-month return-35.7%-13.5%4th lowest of 21
Distance from 52-week high-59.0%-37.6%2nd lowest of 21
Revenue growth (TTM)-11.9%+13.0%lowest of 21
Operating margin-2.3%14.1%5th lowest of 21
Forward P/E20.5×19.8×7th most expensive of 16
Growth the price implies (Req g, 7 yrs)20.3%3.8%3rd most demanding of 14
Growth delivered (Del g)-0.2%+15.5%2nd lowest of 14
Hurdle (Req g minus delivered)+20.5 pp-12.4 ppmost demanding of 14
ROIC minus cost of capital-4.0 pp+1.1 pp6th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%

Questions

Which companies are Shanghai Runda Medical Technology's closest peers?
The cockpit's peer set: Jiang Xi Sanxin Medtec (300453.SZ), InMode (INMD), Allmed Medical Products (002950.SZ), Beijing Aerospace Changfeng (600855.SS), BMC Medical (301367.SZ), Shanghai Aladdin Biochemical Technology (688179.SS), Sino Medical Sciences Technology (688108.SS), Maccura Biotechnology (300463.SZ).
Is Shanghai Runda Medical Technology expensive compared with its peers?
On forward p/e it trades at 20.5× against a peer median of 19.8×, 7th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shanghai Runda Medical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -35.7% against -13.5% for the median peer; over one year -49.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.